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Bisphenol A (BPA), a compound widely used 
in industry, is present in polycarbonate plas-
tics, epoxy resins, metal cans and water pipes, 
beverage and baby formula bottles, eyeglass 
lenses, toys, sports equipment, dental sealants, 
medical equipment and tubing, and consumer 
electronics (Vandenberg et al. 2007), making 
human exposure very prevalent. BPA has been 
found in serum [0.2–20 ng/mL (0.1–10 µM)] 
and in tissues of men and women of differ-
ent ages and ethnic groups, with the highest 
concentration exceeding 100 ng/g in human 
placenta (Schonfelder et al. 2002). Concern 
about BPA arose in recent years when sev-
eral studies reported adverse effects of this 
chemical on endocrine systems, especially the 
reproductive system and the thyroid (Zoeller 
2007), leading to its designation as an endo-
crine disruptor. BPA exposure at different 
develop  mental stages disrupts meiotic spin-
dle assembly and early oogenesis (Hunt et al. 
2003; Susiarjo et al. 2007; Susiarjo and Hunt 
2008) and steroidogenesis (Akingbemi et al. 
2004; Lee et al. 2006; Mlynarcíková et al. 
2005; Song et al. 2002; Zhou et al. 2008). 
It also adversely affects the nervous system 
(Farabollini et al. 2002; Wetherill et al. 2007) 
and the immune system (Richter et al. 2007; 
Yoshino et al. 2004). 
Dominant follicle selection, growth, and 
maturation, as well as ovulation, oocyte qual-
ity, and subsequent corpus luteum function, 
depend on sequential actions of gonadotropins 
and intra  ovarian regulators, including the insu-
lin-like growth factor (IGF) system (Fortune 
1994; Kwintkiewicz and Giudice 2009). 
Granulosa aromatase [cytochrome P450 
(CYP) 19] expression, key in the bio  synthesis 
of ovarian-derived 17β-estradiol (E2), is stim-
ulated by pituitary-derived follicle-stimulating 
hormone (FSH) and intra  ovarian IGFs dur-
ing the follicular phase of the menstrual cycle 
(Hillier et al. 1994). FSH-driven aromatase 
expression in the granulosa cell compartment 
of the pre  ovulatory follicle is controlled by 
the ovary-specific proximal PII promoter 
(Bulun et al. 2003) that contains response 
elements for transcription factors that regulate 
aromatase expression. These include steroido-
genic factor-1 (SF-1), LRH-1 (liver receptor 
homolog-1), cAMP response element bind-
ing protein (CREB), and GATA4 (Bouchard 
et al. 2005; Carlone and Richards 1997; 
Kwintkiewicz et al. 2007) with resulting acti-
vation of the protein kinase A and other signal 
transduction pathways (Hunzicker-Dunn and 
Maizels 2006). BPA disrupts gonadal steroido-
genesis in the rodent (Akingbemi et al. 2004; 
Song et al. 2002; Zhou et al. 2008), farm ani-
mals (Mlynarcíková et al. 2005), and wildlife 
species (Lee et al. 2006), although it is not 
clear what the mechanisms are for its actions. 
Interestingly, it has been proposed that despite 
its low affinity to estrogen receptors (ERs) 
compared with endogenous estrogens, BPA 
may act as a selective estrogen receptor modu-
lator by impairing activation of ERα in vari-
ous tissues (Hall and Korach 2002; Kurosawa 
et al. 2002; Routledge et al. 2000; Vivacqua 
et al. 2003).
Herein, we present evidence that exposure 
of human granulosa cells to BPA affects FSH-
induced aromatase and E2 secretion, as well 
as other downstream effectors of FSH action, 
including IGF-1 and the transcription factors 
SF-1 and GATA4. Furthermore, data sug-
gest that BPA may contribute to aromatase 
down-regulation via induction of peroxisome 
proliferator–activated receptor-γ (PPARγ). 
Overall the data suggest that the ubiquitously 
present endocrine disruptor BPA may affect 
the steroidogenic capacity in human ovary 
and seriously affect processes governing nor-
mal reproductive physiology and reproductive 
potential.
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Ba c k g r o u n d: Bisphenol A (BPA), a chemical used as a plasticizer, is a potent endocrine disruptor 
that, even in low concentrations, disturbs normal development and functions of reproductive organs 
in different species.
oBjectives: We investigated whether BPA affects human ovarian granulosa cell function.
Me t h o d s : We treated KGN granulosa cells and granulosa cells from subjects undergoing in vitro 
fertilization (IVF) with follicle-stimulating hormone (FSH), BPA, or BPA plus FSH in a dose- and 
time-dependent manner. We then evaluated expression of insulin-like growth factor 1 (IGF-1), 
aromatase, and transcription factors known to mediate aromatase induction by FSH [including 
steroidogenic factor-1 (SF-1), GATA4, cAMP response element binding protein-1 (CREB-1), and 
peroxisome proliferator–activated receptor-γ (PPARγ)], as well as 17β-estradiol (E2) secretion. KGN 
cells were transfected with a PPARγ-containing vector, followed by assessment of aromatase and 
IGF-I expression.
re s u l t s: BPA reduced FSH-induced IGF-1 and aromatase expression and E2 secretion in a dose-
dependent fashion. Similar effects on aromatase were observed in IVF granulosa cells. SF-1 and 
GATA4, but not CREB-1, were reduced after BPA treatment, although PPARγ, an inhibitor of 
aromatase, was significantly up-regulated by BPA in a dose-dependent manner, with simultaneous 
decrease of aromatase. Over  expression of PPARγ in KGN cells reduced FSH-stimulated aromatase 
and IGF‑1 mRNAs, with increasing concentrations of the transfected expression vector, mimicking 
BPA action. Also, BPA reduced granulosa cell DNA synthesis without changing DNA fragmenta-
tion, suggesting that BPA does not induce apoptosis.
co n c l u s i o n s: Overall, the data demonstrate that BPA induces PPARγ, which mediates down-
regulation of FSH-stimulated IGF-1, SF-1, GATA4, aromatase, and E2 in human granulosa cells. 
These observations support a potential role of altered steroidogenesis and proliferation within the 
ovarian follicular compartment due to this endocrine disruptor.
key w o r d s : aromatase, bisphenol A, estradiol, FSH, granulosa, IGF-1, ovary, PPARγ. Environ 
Health Perspect 118:400–406 (2010).  doi:10.1289/ehp.0901161 available via http://dx.doi.org/ 
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Materials and Methods
Cells, reagents, and cell culture. The KGN 
ovarian granulosa-like tumor cell line, which 
expresses a functional FSH receptor, was estab-
lished from a patient with an invasive ovarian 
granulosa cell carcinoma, as described previ-
ously (Nishi et al. 2001). Frozen stocks of this 
cell line were thawed, and cells were plated in 
24-well plates or 100-mm plates (125,000 cells/
well or 1,000,000 cells/plate, respectively) 
and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 (Invitrogen, Carlsbad, 
CA, USA) at 37°C in 5% CO2 with the addi-
tion of 10% fetal bovine serum (FBS; Hyclone, 
Logan, UT, USA) until 70% confluent. KGN 
cells were then placed in serum-free DMEM/
F12 medium at 37°C for 48 hr before treat-
ments were added.
Human luteinized granulosa cells were 
isolated from follicular aspirates after oocyte 
retrieval from consenting subjects (n = 4) at 
the University of California San Francisco 
(UCSF) Center for Reproductive Health, 
under a protocol approved by the UCSF 
Committee on Human Research. Subjects 
(32 ± 3.3 years of age, mean ± SD) had 
undergone super  ovulation with gonadotro-
pins after down-regu  lation with a gonadotro-
pin-releasing hormone agonist. In all cases, 
oocyte retrieval was performed for treatment 
of male factor infertility. Human luteinized 
granulosa cells in follicular aspirates under-
went a series of washes with calcium/
magnesium-free phosphate-buffered saline 
(PBS) and were then centrifuged at 200 × g. 
Separation from blood cells was achieved 
on a Ficoll gradient, after which cells were 
plated in 24-well plates (125,000 cells/well) 
and cultured in DMEM/F12 at 37°C in 5% 
CO2 with the addition of 10% FBS until 
70% confluent. Cells were then incubated 
in serum-free DMEM/F12 at 37°C for 48 hr 
before treatments were added.
OPTI-MEM medium and other cell cul-
ture reagents were purchased from Invitrogen. 
Human FSH (containing < 2% luteinizing hor-
mone and < 1% each of thyroid-stimulating 
hormone, growth hormone, prolactin, and 
adreno  cortico  tropic hormone), BPA, (purity 
> 99%), and 4-androstene-3,17-dione (purity 
> 99%) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).
RNA isolation and real‑time polymerase 
chain reaction (PCR). Total RNA from granu-
losa cells was isolated using TRIzol reagent 
(Invitrogen) following the manufacturer’s 
instructions. For mRNA analysis by reverse 
transcriptase PCR (RT-PCR), 0.5–1 µg of 
total RNA was reverse-transcribed at 42°C for 
60 min using 200 U/µL M-MLV (Moloney 
murine leukemia virus) reverse transcriptase 
(Promega, Madison, WI, USA) in the presence 
of oligo(dT)12–18 primer (0.04 µg/µg of total 
RNA), 1 mM dNTP mix, and RNaseOUT 
ribonuclease inhibitor (1 U/µL; Invitrogen). 
After transcription, samples were diluted to 
a final volume of 200 µL with diethyl pyro-
carbonate (DEPC)-treated water. Aliquots 
(5 µL) of sample cDNA were combined with 
Brilliant SYBR Green IQPCR Mastermix 
(Stratagene, La Jolla, CA, USA), specific prim-
ers for human aromatase (CYP19), GATA4, 
SF-1, CREB, PPARγ, or L19, and water to 
a final volume of 25 µL. Intron-spanning 
primers were used for amplification of 
CYP19:   (forward 5´-tgcatggcaagctctcctca-3´ 
and reverse 5´-tttgcgcatgaccaagtcca-3´), 
GATA4 (forward 5´-tggcctgtcatctcactacg-3´ 
and reverse 5´-aagaccaggctgttccaaga-3´), 
SF-1 (  forward 5´-ctcaagttcatcatcctctt-3´ and 
reverse 5´-aggtactccttggcctgcat-3´), CREB 
( forward 5´-ctagcactattgcccctgga-3´ and 
reverse 5´-tttcaagcactgccactctg-3´), PPARγ 
(  forward 5´-gagggccaaggcttcatga-3´ and 
reverse 5´-aggctttcgcaggctctttag-3´), and L19 
(  forward 5´-gcagataatgggaggagcc-3´ and reverse 
5´-gcccatctttgatgagcttc-3´). Real-time quanti-
fication of the PCR product in each cycle was 
carried out using an Mx3005 QPCR system 
(Stratagene) with the following cycling condi-
tions: preincubation at 95°C for 15 min, fol-
lowed by 40 cycles of denaturation at 95°C 
for 15 sec, annealing at 58°C for 45 sec, and 
extension at 72°C for 60 sec. The melting peak 
of each sample was routinely determined by 
melting curve analysis to ascertain that only 
the expected products had been generated. The 
minimal number of cycles sufficient to produce 
detectable levels of fluorescence (cycle thresh-
old) was calculated using MxPro software 
(Stratagene). For each gene, the amplification 
efficiency of the primer set was determined by 
performing quantitative PCR using a dilution 
series of the cDNA as a template, as previously 
described (Nyegaard et al. 2010).
E2 enzyme‑linked immuno  sorbent assay 
(ELISA). We determined E2 in conditioned 
media using the ELISA kit from Bio-quant 
(San Diego, CA, USA) following the manufac-
turer’s instructions. Briefly, cells were treated 
with FSH and/or BPA in the presence of 
4-androstene-3,17-dione; 48 hr later medium 
was collected, properly diluted, and stored at 
–80°C or immediately analyzed. Standards 
and positive controls (provided in the kit) or 
samples were placed into the wells of a micro-
plate, along with the E2–horseradish peroxi-
dase conjugate and rabbit anti-E2 reagent, 
and incubated for 2 hr at room temperature. 
Afterward, samples were decanted and wells 
were washed extensively. Finally, a stabilized 
chromogen was added, and the colorimet-
ric reaction was developed within 30 min, 
after which “stop solution” was added and the 
absorbance was measured on a spectropho-
tometer at 450 nm. Additionally, remaining 
cells were homogenized in protein lysis buffer 
[10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1 mM sodium 
fluoride, 20 mM sodium diphosphate, 2 mM 
sodium orthovanadate, 1% Triton X-100, 
10% glycerol, 0.1% sodium dodecyl sulfate 
(SDS), 0.5% deoxycholate], and the pro-
tein concentration in each well was meas-
ured. Final data are plotted as picograms of 
synthesized E2 per microgram of total pro-
tein. Cross-reactivity with estrone and estriol 
approximated 2.1% and 1.5%, respectively 
(the percentage indicates cross-reactivity at 
50% displacement compared with E2).
Western blot analysis. After adding treat-
ments, we cultured cells for various periods of 
time; subsequently, media were removed and 
cells were washed with ice-cold PBS. Cytosolic 
fractions were prepared to evaluate aromatase 
levels, and nuclear fractions were used to 
assess the expression of PPARγ protein. Cells 
were lysed in “lysis buffer” (Pierce, Rockford, 
IL, USA), and proteins were extracted accord-
ing to the manufacturer’s instructions. Briefly, 
cells were homogenized in lysis buffer I (cyto-
solic) and kept on ice for 10 min, after which 
suspensions were centrifuged at 16,000 × g 
for 5 min and supernatants (cytosolic frac-
tion) were collected and stored at –80°C until 
analysis. The remaining pellets were resus-
pended in lysis buffer II (nuclear) and vigor-
ously vortexed for 40 min at 4°C. The nuclear 
suspensions were centrifuged at 16,000 × g 
for 10 min, and supernatants (nuclear frac-
tion) were collected and stored at –80°C until 
analysis. Shortly before Western blotting was 
performed, protein extracts were quantified 
using the BCA (bicinchoninic acid) Protein 
Assay Kit (Pierce). SDS–polyacrylamide gel 
electrophoresis was run on pre  casted, 4–20% 
Tris-HCl mini  gels for 1.5 hr at 120 V, and 
proteins were subsequently transferred onto 
polyvinylidene difluoride (PVDF) membranes 
in transfer buffer (25 mM Tris, 192 mM gly-
cine, 20% vol/vol methanol, pH 8.3) for 1 hr 
at 50 V. Membranes were blocked with 5% 
milk/Tris-buffered saline–Tween 20, -T, and 
antibody incubation was performed overnight 
at 4°C. We used the following anti  bodies: aro-
matase (MCA2077S; Serotec, Raleigh, NC, 
USA), and actin (sc1616), PPARγ (sc7273), 
and lamin A/C (sc20681; all from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). To 
analyze loading accuracy, PVDF membranes 
were stripped in Western Blot Stripping 
Buffer (Pierce). Western blots were visual-
ized using SuperSignal West Femto Trial kit 
(Pierce) or Lumigen PS-3 detection reagent 
(GE Healthcare, Pittsburgh, PA, USA), 
according to the manu  facturer’s instructions. 
Developed immunoblots were exposed to 
high-performance chemiluminescence film 
(GE Healthcare). 
Plasmids and cell transfection.  We 
obtained expression and control empty 
pBabe-bleo plasmids from R. Kahn (Joslin Kwintkiewicz et al.
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Diabetes Center, Boston, MA, USA) and 
R. Weinberg (Massachusetts Institute of 
Technology, Cambridge, MA, USA), respec-
tively. Cells were seeded in 12-well plates 
in DMEM/F12 medium and incubated for 
2 hr at 37°C. Meanwhile, 1 µL FUGENE 6 
transfection reagent (Roche, Indianapolis, IN, 
USA) and 0.25 µg plasmid DNA per well were 
combined in 100 µL OPTI-MEM medium 
and allowed to incubate for 20 min at room 
temperature. Subsequently, the complexes 
were added to cells and incubated for another 
2 hr at 37°C before treatments were added. 
Empty pBabe-bleo vector was added to keep 
the amount of transfected DNA constant in 
the PPARγ dose–response experiments.
Bromodeoxyuridine (BrdU) ELISA. BrdU 
incorporation ELISA (Roche) was carried out 
according to the manufacturer’s instructions. 
Briefly, cells were seeded in 96-well plates and 
treated with tested additives. BrdU labeling 
solution (10 µL) was added to each 100 µL of 
culture medium for the last 12 hr of culture. 
Afterward, culture medium was decanted, and 
cells were fixed with 200 µL FixDenat solu-
tion (Roche) for 30 min at room temperature. 
Subsequently anti-BrdU working solution 
was added (100 µL/well) and incubated at 
room temperature for another 1.5 hr; after 
extensive washes, the colorimetric reaction 
was developed by adding the substrate solu-
tion. After 30 min the reaction was stopped 
by adding 1 M sulfuric acid, and the absor-
bance was measured at 450 nm. Results are 
presented as fold decrease and plotted as per-
centage of control.
MTS proliferation assay. We performed 
the MTS cell proliferation assay (Promega), 
which is typically used to determine the num-
ber of viable cells in proliferation or cyto-
toxicity assays, according to the manufacturer’s 
instructions. Briefly, 20 µL of staining solu-
tion was added to cells at the end of respective 
treatments, and after 1–4 hr of incubation, 
MTS tetrazolium compound [3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt] 
was bioreduced by cells into a color forma-
zan product, soluble in culture medium. The 
absorbance was measured at 490 nm, and 
results are presented in the same fashion as for 
the BrdU incorporation experiments.
Low‑molecular‑weight DNA apoptotic lad‑
der assay. We performed the low-molecular- 
weight DNA apoptotic assay (Roche) accord-
ing to the manufacturer’s instructions. 
Briefly, at the conclusion of the cell culture 
studies, we added 200 µL/well of binding/
lysis buffer to the cells and incubated them 
for 15 min at room temperature. DNA was 
precipitated by adding isopropanol, followed 
by vigorous shaking. Afterward, samples were 
run through DNA binding columns and 
spun gently. DNA was then washed twice 
with ethanol, eluted from columns by add-
ing 200 µL water, followed by centrifuga-
tion. The final product was mixed with DNA 
loading buffer and subjected to 1% agarose 
electrophoresis for 2 hr at 75 V. Gels were 
then analyzed on the Bio-Rad Gel Doc ultra-
violet camera system (Bio-Rad, Hercules, 
CA, USA). We purchased 20× TAE DNA 
electrophoresis buffer from Qiagen (Valencia, 
CA, USA); agarose and ethidium bromide 
were from Sigma-Aldrich, and 10× BlueJuice 
DNA gel loading buffer was purchased from 
Invitrogen.
Statistical analysis. We performed statisti-
cal analysis using Prism software (GraphPad 
Software, Inc., San Diego, CA, USA). One-
way analysis of variance (ANOVA), followed 
by the Tukey test, was used for all analyses. 
Results
BPA reduces FSH‑induced IGF‑1 and aro‑
matase expression, and E2 synthesis. KGN 
cells express a functional FSH receptor (Nishi 
et al. 2001). Using this cell line, we found 
that FSH-induced expression of IGF-1, a fac-
tor known to play a crucial role in granulosa 
proliferation and steroidogenesis, was dra-
matically reduced by administration of BPA 
in a dose-dependent fashion (Figure 1A). 
With regard to aromatase, another FSH-
stimulated gene in granulosa cells, treatment 
with 40–100 ng/mL FSH for 48 hr produced 
an optimal response (4.5-fold increase of aro-
matase mRNA; Figure 1B, inset). BPA causes 
down-regulation of FSH-induced aromatase 
mRNA expression in a dose-dependent fash-
ion, reducing its expression to the level of 
control at the highest (60–100 µM) concen-
trations (Figure 1B). Consistent with the 
aromatase expression pattern, FSH-induced 
E2 synthesis was significantly reduced by 
BPA to the level observed in untreated cells 
(Figure 1C). Additionally, a similar response 
was observed with human luteinized granulosa 
cells cultured in the presence of FSH with and 
without BPA (Figure 1D). However, a sharp 
decrease in FSH-induced aromatase after BPA 
treatment in these cells occurred when the 
lowest tested concentration (40 µM) of BPA 
was used. BPA had no effect alone on IGF-1, 
aromatase, or E2 production by KGN cells 
(data not shown).
Figure 1. Effects of BPA on IGF‑1, aromatase (CYP19), and E2 production by KGN cells and aromatase expres‑
sion in human luteinized granulosa cells. (A) Dose–response inhibitory effects of BPA on rela  tive expression 
of FSH‑stimulated IGF‑1 mRNA after 48 hr of treatment. (B) Dose–response inhibitory effects of BPA on 
expression of FSH‑stimulated aromatase (CYP19) mRNA after 48 hr of treatment. The insets represent dose–
response (top) and time‑course (bottom) experiments indicating the highest and most optimal response of 
KGN cells in terms of CYP19 expression at 48 hr with 100 ng/mL FSH. (C) Effects of BPA on FSH‑induced E2 
secretion by KGN cells. Prominent reduction of E2 synthesis is noted at 80 and 100 µM BPA; Results were 
derived as pg E2/µg protein and are expressed as percentage of control. (D) Dose–response inhibitory effects 
of BPA on FSH‑stimulated aromatase mRNA expression in human luteinized granulosa cells after 48 hr treat‑
ment. For all experiments, n = 5. 
*p < 0.05 versus control; **p < 0.05 versus FSH; #p < 0.001 versus control; and ##p < 0.001 versus FSH, all by ANOVA, Tukey. 
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BPA affects expression of aromatase regu‑
lators. In an effort to determine what tran-
scription factors may be affected by BPA 
inhibition of FSH-induced aromatase, we 
investigated the expression of select aromatase 
regulators: GATA4, SF-1, CREB (positive 
regulators of aromatase), and PPARγ (a nega-
tive regulator of aromatase), using KGN cells 
and the same experimental design described 
above. As shown in Figure 2A, the expres-
sion pattern of GATA4 is nearly identical to 
that of aromatase, being elevated by FSH and 
reduced by BPA in a dose-dependent fash-
ion, with GATA4 expression reduced to the 
level of control at 80 and 100 µM concentra-
tions of BPA. SF-1 followed a similar trend, 
although the changes showed a trend to sig-
nificance (p < 0.054). However, a post hoc 
test for linear trend revealed statistical sig-
nificance (p < 0.004). Interestingly, expression 
of CREB did not change, whereas expres-
sion of PPARγ, a factor that has been shown 
to participate in the inhibition of aromatase 
in KGN cells (Fan et al. 2005), increased 
with increasing concentrations of BPA. To 
determine if PPARγ mRNA accumulation 
was due to FSH or FSH plus BPA (because 
these two additives were always adminis  tered 
together), we conducted a time-course exper-
iment (Figure 2B). PPARγ expression was 
significantly elevated by 24 hr and sustained 
through 48 hr, and this was observed only in 
cultures in which FSH plus BPA were added 
concomitantly. Furthermore, BPA increased 
nuclear accumulation of PPARγ protein and 
also reduced FSH-induced aromatase pro-
tein levels in KGN cells, which confirmed the 
PCR results (Figure 2C).
We further investigated the effects of 
BPA on the expression of PPARγ in human 
luteinized granulosa cells (Figure 2D) and 
observed that BPA increased PPARγ mRNA 
by 7-fold at the highest concentration 
(100 µM). The response of human luteinized 
granulosa cells to BPA, in terms of PPARγ 
expression, was greater than that of KGN cells 
at low concentrations (40 mM). We observed 
the same trend with aromatase, suggesting 
that the human luteinizing granulosa cells 
are more sensitive to this endocrine disruptor 
in lower concentrations, compared with the 
KGN cell line.
Overexpression of PPARγ mimics BPA 
action. To determine whether over  expression 
of PPARγ mimics BPA action, we transfected 
into KGN cells two doses of pBabe-bleo 
expression vector, either empty or carrying 
the PPARγ sequence, and treated the trans-
fected cells with and without FSH. As shown 
in Figure 3A, FSH-induced aromatase is 
down-regulated with increasing concentra-
tions of the PPARγ vector, and there was a 
similar trend of IGF-1 down-regulation 
(Figure 3C). A Western blot was performed to 
validate the presence of expressed PPARγ pro-
tein (Figure 3B). Together, these data confirm 
that increasing PPARγ expression mimics the 
action of BPA.
We also attempted RNA interference 
experiments to elucidate the affects of BPA on 
PPARγ expression. However, the combina-
tion of BPA and small interfering RNA trans-
fection reagents appeared to be toxic to the 
KGN cells, even at low BPA concentrations 
(data not shown). Furthermore, addition of 
the PPARγ antagonist GW9626 to cells 1 hr 
before BPA treatment did not restore aro-
matase expression reduced by BPA (data not 
Figure 2. Effects of BPA on granulosa transcription factors. (A) Effects of FSH and FSH plus BPA (after 
48 hr treatment) on mRNA expression of transcription factors known to be involved in FSH‑induction of 
aromatase (GATA4, SF‑1, CREB, and PPARγ). A post hoc linear trend test was used to analyze changes 
of SF‑1 expression (n = 5 for each treatment group). (B) Stimulatory effects of BPA and FSH on relative 
expression of PPARγ in KGN cells over a 48‑hr time course. Cells were treated with FSH (100 ng/mL) with 
or without BPA (100 µM) (n = 3 for each treatment group). (C) Effects of BPA on FSH‑induced aromatase 
and PPARγ protein level in KGN cells, shown by representative Western blots for aromatase (CYP19) sub‑
sequently reprobed for total actin (cytoplasmic normalizer), PPARγ, and lamin A/C (nuclear normalizer). 
FSH and BPA were added to KGN cells at 100 ng/mL and 100 µM, respectively. (D) Dose–response stimula‑
tory effects of BPA on expression of PPARγ mRNA in human luteinized granulosa cells in the presence of 
FSH after 48 hr treatment (n = 3 for each treatment group). For A, B, and D, data are mean ± SEM. 
*p < 0.05 versus control; #p < 0.001 versus control; and ##p < 0.001 versus FSH all by ANOVA, Tukey. 
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Figure 3. Overexpression of PPARγ mimics the 
effects of BPA on FSH‑stimulated aromatase and 
IGF‑1 expression. KGN granulosa cells were trans‑
fected with increasing amounts of the pBabe‑bleo 
human PPARγ expression vector [the total amount 
of DNA was kept constant in all samples (0.25 µg/
well) by adding empty plasmid (pBabe‑bleo)]. Cells 
were treated simultaneously with FSH (100 ng/
mL) to show effects of PPARγ expression on FSH‑
stimulated aromatase (A) and IGF‑1 (C). A validating 
PPARγ immunoblot (B) was performed to evaluate 
the level of expressed PPARγ protein in this experi‑
ment. For A and C, n = 5. 
†p < 0.001 versus control; and ††p < 0.01 versus FSH, both 
by ANOVA, Tukey.
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shown), likely because BPA-increased PPARγ 
expression peaks after 48 hr, when the action 
of the antagonist is no longer present. Thus, 
the over  expression data are the most robust 
evidence of PPARγ mimicking BPA action in 
granulosa cells.
BPA inhibits proliferation of KGN granu‑
losa cells. To determine if BPA affects granu-
losa cell proliferation, we conducted BrdU 
incorporation studies. As shown in Figure 4A, 
BPA inhibits KGN cell proliferation in a 
dose-dependent fashion, with maximum inhi-
bition of 92 ± 2% at 100 µM BPA, com-
pared with cells cultured with no additives. 
In a parallel assay evaluating cell viability, we 
observed a trend (Figure 4B) similar to that 
of proliferation (Figure 4A), although maxi-
mum reduction in cell viability (31 ± 3%) was 
achieved at 50 µM without further change at 
higher concentrations of BPA. To determine 
whether these changes were accompanied by 
cellular apoptosis, we conducted DNA ladder-
ing experiments. Low-molecular-weight DNA 
from cells treated with BPA at two different 
concentrations revealed no DNA fragmenta-
tion after BPA treatment, compared with cells 
treated with camptothecin, a known inducer 
of apoptosis (Figure 4C).
Discussion
In the present study we found that the ubiq-
uitous endocrine disruptor BPA impairs 
FSH-stimulated processes involved in ovar-
ian steroidogenesis in human granulosa cells, 
including IGF-1 mRNA expression, aro-
matase mRNA and protein, transcription fac-
tors involved in FSH-stimulated aromatase 
regulation, and E2 production. Furthermore, 
this inhibition occurs through accumulation 
of PPARγ, a member of the nuclear receptor 
superfamily of ligand-dependent transcription 
factors (Knouff and Auwerx 2004). Since its 
discovery, PPARγ activation has been mainly 
associated with processes such as increased 
fatty acid uptake and energy expenditure in 
liver, adipose tissue, and macrophages, as well 
as glucose uptake in muscle and adipocytes 
(Auwerx et al. 2003). However, PPARγ has 
also been shown to play important roles in 
regulating ovarian follicle development, 
ovulation, oocyte maturation, and mainte-
nance of the corpus luteum by enhancing or 
inhibiting steroido  genesis, angio  genesis, tis-
sue remodeling, the cell cycle, apoptosis, and 
lipid metabo  lism (Froment et al. 2006; Komar 
2005). These processes are critical for nor-
mal ovarian function, so it is of significance 
that they are regulated by BPA, which alters 
expression of this nuclear receptor. It has been 
shown that PPARs are involved in the down-
regulation of aromatase and estrogen synthesis 
as a consequence of phthalates, another class 
of ubiquitous environmental contaminant/
endocrine disruptor (Lovekamp and Davis 
2001; Lovekamp-Swan and Davis 2003; 
Lovekamp-Swan et al. 2003). Fan et al. (2005) 
demon  strated that activation of PPARγ down-
regulates aromatase in human granulosa cells 
via inhibition of nuclear factor κB (NF-κB), 
a protein kinase C–dependent transcription 
factor (Diaz-Meco et al. 1993), which under 
physiologic conditions may compete with 
other nuclear receptors (e.g., SF-1, CREB, 
GATA4) to regulate aromatase, despite the 
absence of NF-κB’s binding domain in the 
aromatase proximal promoter. In the pres-
ent study we provide evidence for a second 
potential mechanism responsible for aromatase 
inhibition, namely, via BPA-induced decrease 
of GATA4 and SF-1 transcription factors. 
Whether changes in expression of these regula-
tors are directly involved in the BPA-mediated 
decrease in IGF-1 and CYP19 expression at 
the transcriptional level is of interest and wor-
thy of further investigation.
An increasing body of evidence describ-
ing mechanisms involved in FSH-stimulated 
aromatase expression includes activation of the 
well-established array of cAMP-regulated tran-
scription factors. It is also well documented 
that granulosa cell proliferation and steroido-
genesis are a result not only of   genera  tion 
of cAMP upon ligand binding to the FSH 
receptor, but also of synergistic action of 
IGFs (Khamsi et al. 2001; Kwintkiewicz and 
Giudice 2009), locally synthesized or derived 
from the circulation. Interestingly, we also 
observed that BPA treatment dramatically 
reduced expression of IGF-1, thereby reducing 
IGF/FSH synergy, thus providing additional 
support for BPA as an endocrine disruptor. 
We observed that the reduction of IGF-1 by 
BPA may potentially be achieved through up-
regulation of PPARγ because its over  expression 
revealed a trend to reduce IGF-1 expression, 
suggesting a key role of this nuclear receptor 
in BPA-mediated disruption of FSH-induced 
functions in granulosa cells. A recent study 
by Lecka-Czernik et al. (2007) demon  strated 
that rosiglitazone, a PPARγ agonist, suppresses 
components of the IGF regulatory system in 
different cell types, specifically blocking IGF-1 
and IGF-2, as well as type 1 and type 2 IGF 
receptor expression, and that this is achieved 
by activation of PPARγ. This observation is 
in concordance with our findings and sug-
gests that disruption of the ovarian IGF system 
may be one of several possible mechanisms by 
which the endocrine disruptor BPA exerts its 
effect on E2 biosynthesis in granulosa cells in 
the ovary. 
Another important FSH/IGF-regulated 
function is follicular expansion driven by 
extensive proliferation of granulosa cells. 
Interestingly, in the present study our prolif-
eration experiments demonstrated that granu-
losa cell BrdU incorporation was inhibited 
with increasing concentrations of BPA in the 
absence of cellular apoptosis. Furthermore, 
BPA exposure causes accumulation of PPARγ, 
with concomitant down-regulation of aro-
matase in human granulosa cells. Although 
precise mechanisms under  lying PPARγ 
regulation by BPA and down-regulation of 
FSH-induced aromatase by over  expression 
of PPARγ in the presence of BPA in human 
granulosa cells are uncertain, some key obser-
vations in other systems may give insight into 
these regulatory processes. For example, BPA 
promotes rapid induction of non  genomic sys-
tems such as the mitogen-activated protein 
kinase (MAPK) pathway (Zsarnovszky et al. 
2005), and through activation of this signal-
ing cascade, BPA acts to modulate PPARγ 
activity. Activation of PPARγ may be achieved 
through ligand binding or by its phosphoryla-
tion through stimulation of signal transduc-
tion pathways such as MAPK (Chen et al. 
2003). Although it seems that BPA is not a 
likely candidate to be a PPARγ ligand, it is 
known to activate—at nanomolar range con-
centrations—components of the MAPK path-
way, such as phosphorylation of extra  cellular 
regulated protein kinase (Erk) 1/2 (Song et al. 
2002; Zsarnovszky et al. 2005). Thus, ele-
vated expression of PPARγ by BPA may be 
Figure 4. Effects of 48‑hr BPA treatment on KGN cell survival, proliferation, and apoptosis. OD, optical 
density. (A) Effects of BPA on cell proliferation (BrdU incorporation). (B) Effects of BPA on cell viability; 
conversion of MTS tetrazolium to formazan corresponds directly with the metabolic status of living cells 
in culture. (C) DNA laddering of low‑molecular‑weight DNA; the positive control (PC) was 3 µM camptoth‑
ecin. For each group, n = 8.
†p < 0.01 versus control by ANOVA, Tukey. 
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potentially important for its final activation, 
which occurs independently of the increase 
of its mRNA and protein level. Previous stud-
ies demonstrate that troglitazone-triggered 
activation of PPARγ leads to inhibition 
of aromatase via NF-κB (Fan et al. 2005), 
which provides a rationale and evidence that 
activated PPARγ contributes to the down- 
regulation of aromatase. Also, activation of 
Erk1/2 leads to phosphorylation of PPARγ, 
which leads to its physical association with 
the p65 subunit of NF-κB (Chen et al. 2003), 
supporting NF-κB as a mediator of BPA-
associated aromatase inhibition. Further stud-
ies are needed to elucidate the role of NF-κB 
and the MAPK pathway in BPA-mediated 
aromatase inhibition in human granulosa cells.
Of interest are the dramatic and some-
what surprising results of BPA inhibition of 
BrdU incorporation (Figure 4) in the KGN 
cell line, in the absence of cellular apoptosis 
and cell death. It would be anticipated that 
at higher doses the cell numbers would be 
lower than at lower doses and that this may 
affect the results. However, because the data 
have been analyzed and reported as relative 
expression to a normalizer (e.g., actin or total 
protein), it is unlikely that this inhibition of 
DNA synthesis would change the interpreta-
tion of our data. 
BPA has been shown to act on cells to 
modulate the state of their DNA methyla-
tion, ultimately altering promoter activity of, 
for example, ERα in the rat brain (Monje 
et al. 2007) or by decreasing cytosine–guanine 
dinucleotide methylation, causing pre  natal 
epigenetic reprogramming (Dolinoy et al. 
2007). Whether such actions (and others) of 
BPA are operational in regulation of PPARγ 
in human granulosa cells is currently under 
investigation in our laboratories.
The full impact of BPA as an endocrine 
disruptor in human ovarian steroido  genesis 
during adult exposures to this compound and 
the potential effects on compromised fertility 
remain to be elucidated. However, a recent 
preliminary report demonstrated an inverse 
correlation between serum levels of BPA 
(maximum of 30 nM) and lower fertili  za  tion 
rates of oocytes derived from women under-
going in vitro fertilization (IVF) (Lamb et al. 
2008). These data thus suggest that BPA, a 
ubiquitous endocrine disruptor, may affect 
human granulosa steroido  genic potential 
in vivo and female fertility. In the present 
study, the effects of BPA on FSH-stimulated 
processes occurred at relatively high concen-
trations, with human luteinized granulosa 
cells seemingly more sensitive than the KGN 
cell line. Although circulating levels of BPA 
are lower than those used in our experiments, 
it is unclear whether women attain such high 
levels of BPA in their serum or follicular fluid 
by exposure to this chemical; such elevation 
of BPA would likely be transient after a spe-
cific exposure because BPA is not a persistent 
chemical. However, repeated exposures to 
a multitude of consumer products contain-
ing this endocrine disruptor may result in 
high concentrations. Given that high doses 
of BPA have such a profound effect on gran-
ulosa steroido  genesis, disruption of ovarian 
steroido  genesis leading to decreased reproduc-
tive potential is a real possibility. Minimizing 
such exposures to maximize reproductive 
potential, although not proven, is prudent in 
view of our data. 
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